Cargando…

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells

NKT cells, a novel murine lymphoid lineage bearing an invariant T cell receptor encoded by Vα14 and Jα281 gene segments, recognize a specific ligand glycolipid, α‐galactosylceramide (α‐GalCer) in a CDld‐dependent manner. Recent research has revealed that activated Vα14 NKT cells have dramatic antitu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akutsu, Yasunori, Nakayama, Toshinori, Harada, Michishige, Kawano, Tetsu, Motohashi, Shinichiro, Shimizu, Eiko, Ito, Toshihiro, Kamada, Noriaki, Saito, Takeshi, Matsubara, Hisahiro, Miyazawa, Yukimasa, Ochiai, Takenori, Taniguchi, Masaru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2002
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927009/ https://www.ncbi.nlm.nih.gov/pubmed/11985789 http://dx.doi.org/10.1111/j.1349-7006.2002.tb01270.x

Ejemplares similares

Augmentation of Vα14 Nkt Cell–Mediated Cytotoxicity by Interleukin 4 in an Autocrine Mechanism Resulting in the Development of Concanavalin a–Induced Hepatitis
por: Kaneko, Yoshikatsu, et al.
Publicado: (2000)

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
por: Kitamura, Hidemitsu, et al.
Publicado: (1999)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

NKT Cell Stimulation with α-Galactosylceramide Results in a Block of Th17 Differentiation after Intranasal Immunization in Mice
por: Zygmunt, Beata M., et al.
Publicado: (2012)

Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
por: TANIGUCHI, Masaru, et al.
Publicado: (2015)

α-Galactosylceramide Analogs with Weak Agonist Activity for Human iNKT Cells Define New Candidate Anti-Inflammatory Agents
por: Bricard, Gabriel, et al.
Publicado: (2010)

Activation of Invariant NKT Cells with Glycolipid Ligand α-Galactosylceramide Ameliorates Glucose-6-Phosphate Isomerase Peptide-Induced Arthritis
por: Horikoshi, Masanobu, et al.
Publicado: (2012)

Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy
por: Singh, M, et al.
Publicado: (2014)

NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
por: Toyoda, Takahide, et al.
Publicado: (2020)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

A case of small-cell esophageal cancer with chronic renal failure undergoing hemodialysis safely treated with cisplatin and etoposide
por: Murakami, Kentaro, et al.
Publicado: (2011)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
por: Singh, Shailbala, et al.
Publicado: (2014)

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer
por: Wu, Chao-Chih, et al.
Publicado: (2013)

Production of α-Galactosylceramide by a Prominent Member of the Human Gut Microbiota
por: Wieland Brown, Laura C., et al.
Publicado: (2013)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
por: Artiaga, Bianca L., et al.
Publicado: (2022)

Efficient synthesis of α-galactosylceramide and its C-6 modified analogs
por: Li, Huiting, et al.
Publicado: (2022)

Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in Bacteroides fragilis
por: Caballé, Marc, et al.
Publicado: (2022)

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues
por: Janssens, Jonas, et al.
Publicado: (2017)

Synthesis and Immunological Activity of Novel Oligo(ethylene glycol) Analogues of α-Galactosylceramide
por: Pawar, Mithun S., et al.
Publicado: (2022)

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine
por: Gableh, Fateme, et al.
Publicado: (2016)

Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
por: Aoki, Takahiro, et al.
Publicado: (2023)

Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide
por: Nowak, Michael, et al.
Publicado: (2010)

The Molecular Basis for Recognition of CD1d/α-Galactosylceramide by a Human Non-Vα24 T Cell Receptor
por: López-Sagaseta, Jacinto, et al.
Publicado: (2012)

Tumor-infiltrating effector cells of α-galactosylceramide-induced antitumor immunity in metastatic liver tumor
por: Osada, Takuya, et al.
Publicado: (2004)

α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant
por: Artiaga, Bianca L., et al.
Publicado: (2016)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Thermodynamic and Structural Behavior of α‐Galactosylceramide and C6‐Functionalized α‐GalCer in 2D Layers at the Air–Liquid Interface
por: Brezesinski, Gerald, et al.
Publicado: (2019)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Inhibition of T Helper Cell Type 2 Cell Differentiation and Immunoglobulin E Response by Ligand-Activated Vα14 Natural Killer T Cells
por: Cui, Junqing, et al.
Publicado: (1999)

Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
por: Shimizu, Kanako, et al.
Publicado: (2007)

Invariant NKT cells are resistant to circulating CD15(+) myeloid‐derived suppressor cells in patients with head and neck cancer
por: Horinaka, Atsushi, et al.
Publicado: (2016)

Structure and binding kinetics of three different human CD1d–α-galactosylceramide–specific T cell receptors
por: Gadola, Stephan D., et al.
Publicado: (2006)

Anti-Inflammatory Effects of α-Galactosylceramide Analogs in Activated Microglia: Involvement of the p38 MAPK Signaling Pathway
por: Jeong, Yeon-Hui, et al.
Publicado: (2014)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression
por: Nakamura, Makoto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oea4adl55a448gbem27ic47a9n